Researchers have identified a new compound that in preliminary testing has shown itself to be as effective as antibiotics approved by the FDA to treat life-threatening infections while also appearing to be less susceptible to bacterial resistance. The compound has been potent against antibiotic-resistant pathogens such as MRSA, which is often found in hospitals and other health care settings, and vancomycin-resistant Staphylococcus, with vancomycin long considered a drug of last resort.

The U.S. Food and Drug Administration has approved the first generic versions of Strattera (atomoxetine) to treat attention-deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.

The U.S. Food and Drug Administration has cleared the expanded use of the Vidas Brahms PCT Assay to help health care providers determine if antibiotic treatment should be started or stopped in...

Prescription cough and cold medicines containing the opioid hydrocodone were more likely to cause serious side effects in children than those containing codeine, according to a new study. The research supports recent U.S. Food and Drug Administration (FDA) restrictions on prescription hydrocodone- and codeine-containing cough medicines for children and suggests that opioids in general should not be prescribed for coughs and colds in pediatric populations.